company background image
BIO

BiofarmBVB:BIO Stock Report

Last Price

RON0.79

Market Cap

RON782.4m

7D

-3.9%

1Y

68.9%

Updated

26 Jan, 2022

Data

Company Financials
BIO fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends4/6

BIO Stock Overview

Biofarm S.A. manufactures and sells medicines primarily in Romania.

Biofarm Competitors

Zentiva

BVB:SCD

RON1.6b

Antibiotice

BVB:ATB

RON384.0m

Sanofi

ENXTPA:SAN

€113.3b

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹1.9t

Price History & Performance

Summary of all time highs, changes and price drops for Biofarm
Historical stock prices
Current Share PriceRON0.79
52 Week HighRON0.85
52 Week LowRON0.46
Beta0.28
1 Month Change-4.34%
3 Month Change26.43%
1 Year Change68.94%
3 Year Change136.31%
5 Year Change192.99%
Change since IPO105.28%

Recent News & Updates

Mar 18
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...

Feb 18
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...

Jan 23
Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return

Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return

When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...

Shareholder Returns

BIORO PharmaceuticalsRO Market
7D-3.9%-3.6%-5.1%
1Y68.9%9.9%22.7%

Return vs Industry: BIO exceeded the RO Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: BIO exceeded the RO Market which returned 22.7% over the past year.

Price Volatility

Is BIO's price volatile compared to industry and market?
BIO volatility
BIO Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.4%
10% most volatile stocks in RO Market6.8%
10% least volatile stocks in RO Market2.5%

Stable Share Price: BIO is more volatile than 75% of RO stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BIO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of RO stocks.

About the Company

FoundedEmployeesCEOWebsite
1921369Vicol Constantinhttps://www.biofarm.ro

Biofarm S.A. manufactures and sells medicines primarily in Romania. It offers a portfolio of products covering therapeutic areas, such as anti-allergic, cardiovascular and circulatory, dermatological, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmologic, musculoskeletal, respiratory and ENT, and neurological. The company provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, and other products.

Biofarm Fundamentals Summary

How do Biofarm's earnings and revenue compare to its market cap?
BIO fundamental statistics
Market CapRON782.38m
Earnings (TTM)RON63.55m
Revenue (TTM)RON241.48m

12.3x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIO income statement (TTM)
RevenueRON241.48m
Cost of RevenueRON41.76m
Gross ProfitRON199.72m
ExpensesRON136.17m
EarningsRON63.55m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.064
Gross Margin82.71%
Net Profit Margin26.32%
Debt/Equity Ratio0.0%

How did BIO perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

34%

Payout Ratio

Valuation

Is Biofarm undervalued compared to its fair value and its price relative to the market?

28.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BIO (RON0.79) is trading below our estimate of fair value (RON1.1)

Significantly Below Fair Value: BIO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BIO is good value based on its PE Ratio (12.3x) compared to the European Pharmaceuticals industry average (26.3x).

PE vs Market: BIO is good value based on its PE Ratio (12.3x) compared to the RO market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (2.4x) compared to the XE Pharmaceuticals industry average (2.9x).


Future Growth

How is Biofarm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biofarm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Biofarm performed over the past 5 years?

15.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIO has high quality earnings.

Growing Profit Margin: BIO's current net profit margins (26.3%) are lower than last year (26.3%).


Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown by 15% per year over the past 5 years.

Accelerating Growth: BIO's earnings growth over the past year (12.9%) is below its 5-year average (15% per year).

Earnings vs Industry: BIO earnings growth over the past year (12.9%) exceeded the Pharmaceuticals industry 11.9%.


Return on Equity

High ROE: BIO's Return on Equity (19.5%) is considered low.


Financial Health

How is Biofarm's financial position?


Financial Position Analysis

Short Term Liabilities: BIO's short term assets (RON229.9M) exceed its short term liabilities (RON66.4M).

Long Term Liabilities: BIO's short term assets (RON229.9M) exceed its long term liabilities (RON620.9K).


Debt to Equity History and Analysis

Debt Level: BIO is debt free.

Reducing Debt: BIO has not had any debt for past 5 years.

Debt Coverage: BIO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BIO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Biofarm current dividend yield, its reliability and sustainability?

2.77%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BIO's dividend (2.77%) is higher than the bottom 25% of dividend payers in the RO market (2.76%).

High Dividend: BIO's dividend (2.77%) is low compared to the top 25% of dividend payers in the RO market (5.82%).


Stability and Growth of Payments

Stable Dividend: BIO's dividends per share have been stable in the past 10 years.

Growing Dividend: BIO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.1%), BIO's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Vicol Constantin (47 yo)

3.17yrs

Tenure

Vicol Catalin Constantin serves as Director and General Manager at Biofarm S.A.


Leadership Team

Experienced Management: BIO's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: BIO's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biofarm S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biofarm S.A.
  • Ticker: BIO
  • Exchange: BVB
  • Founded: 1921
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RON782.382m
  • Shares outstanding: 985.37m
  • Website: https://www.biofarm.ro

Number of Employees


Location

  • Biofarm S.A.
  • 99 Logofatul Tautu Street
  • Sector 3
  • Bucharest
  • 31212
  • Romania

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/26 22:25
End of Day Share Price2022/01/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.